Genetic Analysis AS (FRA:8V8) ROCE % : -63.28% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Genetic Analysis AS ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genetic Analysis AS's annualized ROCE % for the quarter that ended in Mar. 2024 was -63.28%.

Genetic Analysis AS ROCE % Historical Data

The historical data trend for Genetic Analysis AS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Analysis AS ROCE % Chart

Genetic Analysis AS Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-18.55

-50.75

-48.31

-44.23

-50.11

Genetic Analysis AS Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial											-58.60	-51.91	-48.32	-74.61	-63.28

Genetic Analysis AS ROCE % Calculation

Genetic Analysis AS's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-2.048	/	( ( (6.156 - 1.237)	+	(4.65 - 1.395) )	/ 2 )
	=	-2.048	/	( (4.919	+	3.255)	/ 2 )
	=	-2.048	/	4.087
	=	-50.11 %

Genetic Analysis AS's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-1.888	/	( ( (4.65 - 1.395)	+	(3.829 - 1.117) )	/ 2 )
	=	-1.888	/	( ( 3.255	+	2.712 )	/ 2 )
	=	-1.888	/	2.9835
	=	-63.28 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Genetic Analysis AS (FRA:8V8) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Genetic Analysis AS ROCE % Related Terms

Thank you for viewing the detailed overview of Genetic Analysis AS's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Analysis AS (FRA:8V8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Analysis AS (FRA:8V8) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

GEAN:Sweden

Address

Kabelgata 8, Oslo, NOR, 0580

Website

https://www.genetic-analysis.com

Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering innovative diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Genetic Analysis AS (FRA:8V8) Headlines

No Headlines